| Previous Close | 285.70 |
| Open | 288.03 |
| Volume | 318,478 |
| Avg. Volume (3M) | 579,198 |
| Market Cap | 140,056,870,912 |
| Price / Earnings (TTM) | 32.98 |
| Price / Earnings (Forward) | 27.40 |
| Price / Sales | 6.09 |
| Price / Book | 5.24 |
| 52 Weeks Range | |
| Earnings Date | 11 Feb 2025 |
| TTM Dividend Yield | 1.41% |
| Profit Margin | 17.85% |
| Operating Margin (TTM) | 19.02% |
| Diluted EPS (TTM) | 8.73 |
| Quarterly Revenue Growth (YOY) | 10.10% |
| Quarterly Earnings Growth (YOY) | 29.80% |
| Total Debt/Equity (MRQ) | 62.80% |
| Current Ratio (MRQ) | 2.17 |
| Operating Cash Flow (TTM) | 2.76 B |
| Levered Free Cash Flow (TTM) | 1.04 B |
| Return on Assets (TTM) | 6.56% |
| Return on Equity (TTM) | 14.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | CSL FPO [CSL] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Growth |
| % Held by Insiders | 0.30% |
| % Held by Institutions | 37.01% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |